Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-109 in Hidradenitis Suppurativa
NCT04756336Phase 2Completed
- Sponsor
- Pharma
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voxvoganan in hidradenitis suppurativa (HS), sponsored by Pharma. Primary endpoints: Investigator assessed signs for local reactions to the Investigational Medicinal Product at 6 weeks and Patient reported symptoms for local reactions to the Investigational Medicinal Product at 6 weeks. Started Mar 2021; status: completed.
02
Drugs
voxvoganan
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04756336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756336.